Simultaneous Assessment of FFR and SPECT
The Simultaneous Assessment of Invasive Fractional Flow Reserve and SPECT Myocardial Ischemia Using Regadenoson in the Catheterization Laboratory
Sponsor: Astellas Pharma US, Inc.
Terminated
Slow recruitment, funding period ended
Other terminated trials from Astellas Pharma US, Inc.
- Aplastic Anemia · Phase PHASE1 · Apr 2013
- Angina · Phase EARLY_PHASE1 · Mar 2011
- Chest Pain · Phase NA · May 2010
- Hyponatremia · Phase PHASE4 · Feb 2010
- Overactive Bladder · Phase NA · Feb 2010
More terminations from Astellas Pharma US, Inc.
Other Coronary Artery Disease trials with similar outcome
A NA clinical study on Coronary Artery Disease, this trial is terminated or withdrawn. The trial is conducted by Astellas Pharma US, Inc. and has accumulated 10 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2022 — Jul 2024 [monthly]
Terminated NA
Status: Completed → Terminated
-
Oct 2021 — Mar 2022 [monthly]
Completed NA
Status: Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jan 2020 — Oct 2020 [monthly]
Recruiting NA
-
Jan 2019 — Jan 2020 [monthly]
Recruiting NA
-
Jun 2018 — Jan 2019 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma US, Inc.
- Prem Soman
For direct contact, visit the study record on ClinicalTrials.gov .